The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value

[1]  S. Rosenberg.  IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.

[2]  F. Marincola,et al.  What have we learned from cancer immunotherapy in the last 3 years? , 2014, Journal of Translational Medicine.

[3]  Y. Shoenfeld,et al.  IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist , 2014, Nature Reviews Immunology.

[4]  J. L. Daniotti,et al.  Glycosylation of Glycolipids in Cancer: Basis for Development of Novel Therapeutic Approaches , 2013, Front. Oncol..

[5]  M. Shurin,et al.  Role of the Immunological Environment in Cancer Initiation, Development and Progression , 2013 .

[6]  W. Murphy,et al.  Cellular and molecular pathways in the tumor immunoenvironment: 3rd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, 22–25 April 2013, Krakow, Poland , 2013, Cancer Immunology, Immunotherapy.

[7]  Zhigang Tian,et al.  Defining the critical hurdles in cancer immunotherapy , 2011, Journal of Translational Medicine.

[8]  J. Allison,et al.  Single dose of anti–CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance , 2010, Proceedings of the National Academy of Sciences.

[9]  Moses Rodriguez,et al.  Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation , 2009, Clinical and experimental immunology.

[10]  F. Marincola,et al.  Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science. , 2009, Immunotherapy.

[11]  M. Glassy,et al.  Antibody phage display: overview of a powerful technology that has quickly translated to the clinic. , 2009, Methods in molecular biology.

[12]  T. Whiteside,et al.  Histocompatibility Antigens, Tumor Microenvironment and Escape Mechanisms Utilized by Tumor Cells , 2008 .

[13]  I. Witz,et al.  Yin-yang activities and vicious cycles in the tumor microenvironment. , 2008, Cancer research.

[14]  A. Varki,et al.  Diversity in cell surface sialic acid presentations: implications for biology and disease , 2007, Laboratory Investigation.

[15]  D. Morton,et al.  Glycoimmunomics of human cancer: current concepts and future perspectives. , 2007, Future oncology.

[16]  J. Tóth,et al.  Characteristics of tumor gangliosides revealed by B cells infiltrating human breast carcinomas , 2006 .

[17]  W. Fridman,et al.  Novel Ganglioside Antigen Identified by B Cells in Human Medullary Breast Carcinomas: The Proof of Principle Concerning the Tumor-Infiltrating B Lymphocytes1 , 2005, The Journal of Immunology.

[18]  Y. Shoenfeld,et al.  IVIG for Autoimmune, Fibrosis, and Malignant Conditions: Our Experience with 200 Patients , 2004, Journal of Clinical Immunology.

[19]  M. Lotze,et al.  Th1/Th2 balance in cancer, transplantation and pregnancy , 2004, Springer Seminars in Immunopathology.

[20]  H. Vollmers,et al.  Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies. , 2003, Human antibodies.

[21]  S. Hakomori,et al.  Glycosylation defining cancer malignancy: New wine in an old bottle , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Y. Shoenfeld,et al.  IVIG in autoimmunity and cancer – efficacy versus safety , 2002, Expert opinion on drug safety.

[23]  P. Fishman,et al.  A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model. , 2002, International journal of oncology.

[24]  P. Fishman,et al.  Shrinkage of melanoma metastases following high dose intravenous immunoglobulin treatment. , 2001, The Israel Medical Association journal : IMAJ.

[25]  P. Fishman,et al.  Gamma-globulin inhibits tumor spread in mice. , 1999, International immunology.

[26]  W. Fridman,et al.  Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma. , 1997, Immunology letters.

[27]  P. Fishman,et al.  Tyrosinase as an autoantigen in patients with vitiligo , 1996, Clinical and experimental immunology.

[28]  J. Tímár,et al.  Sex-dependent liver metastasis of human melanoma lines in SCID mice , 1995, Melanoma research.

[29]  G. Wong,et al.  Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  I. Witz,et al.  CD5+ B cells and naturally occurring autoantibodies in cancer patients , 1991, Clinical and experimental immunology.

[31]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[32]  S. Hakomori,et al.  Glycosphingolipids as tumor-associated and differentiation markers. , 1983, Journal of the National Cancer Institute.